IFM Investors Pty Ltd acquired a new position in Celgene Corporation (NASDAQ:CELG) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 21,591 shares of the biopharmaceutical company’s stock, valued at approximately $2,804,000.

Other hedge funds have also bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Celgene Corporation in the 1st quarter worth about $118,000. Motco increased its position in Celgene Corporation by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares in the last quarter. Acropolis Investment Management LLC bought a new stake in Celgene Corporation in the 2nd quarter valued at about $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares in the last quarter. Finally, Rational Advisors LLC bought a new stake in Celgene Corporation in the 2nd quarter valued at about $156,000. 78.92% of the stock is owned by hedge funds and other institutional investors.

WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/ifm-investors-pty-ltd-invests-2-80-million-in-celgene-corporation-celg/1697265.html.

A number of analysts recently commented on the company. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $175.00 target price (up from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 target price on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a research report on Friday, October 20th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $160.00 target price (up from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $156.00 target price on shares of Celgene Corporation in a research report on Friday, October 20th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $139.64.

Shares of Celgene Corporation (NASDAQ CELG) opened at $102.34 on Friday. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The stock has a market cap of $80,574.02, a price-to-earnings ratio of 15.99, a price-to-earnings-growth ratio of 0.79 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the firm posted $1.58 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. equities research analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

In other news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,227 shares of company stock worth $2,843,956. Insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.